AzurRx BioPharma CEO Issues Letter to Shareholders
January 08, 2021 09:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
January 04, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
Agreement expands AzurRx’s pipeline of targeted, non-systemic GI therapies Clinical trials to initiate in 1H’21, with potential for expedited FDA 505(b)(2) pathway for IND-approved COVID-19 and...
면역 체크 포인트 억제제 시장은 2025 년까지 $ 56.53 Bn에 도달합니다
April 23, 2020 10:11 ET
|
Allied Market Research
오레곤 주 포틀랜드, April 23, 2020 (GLOBE NEWSWIRE) -- 전 세계 면역 체크 포인트 억제제 시장 의 가치는 2017 년 100 억 5 천 5 백만 달러로, 2025 년까지 5,530 억 달러에이를 것으로 예상되며, 2018 년부터 2025 년까지 연평균 20.1 %의 CAGR을 기록했습니다.이 보고서는 시장을 면밀히...
Immune Checkpoint Inhibitors Market to Reach $56.53 Bn by 2025
April 23, 2020 10:11 ET
|
Allied Market Research
Portland, OR, April 23, 2020 (GLOBE NEWSWIRE) -- The global Immune Checkpoint Inhibitors Market was valued at $10.56 billion in 2017 and is projected to reach $56.53 billion by 2025, registering a...
Global Immune Checkpoint Inhibitors Market to Surpass US$ 40.8 Billion by 2026 - Coherent Market Insights
March 26, 2019 08:30 ET
|
CMI
SEATTLE, March 26, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market was valued at US$ 10,543.8 million in 2017, and is projected to...
Immune Checkpoint Inhibitors Expanding at a booming CAGR of 14.6% during 2018-2026– Persistence Market Research
September 05, 2018 09:30 ET
|
Persistence Market Research
New York, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Attributed to growing demand for the development of biologics targeting cancer therapy, PMR predicts that the immune checkpoint inhibitors will present...